Plenary Session 1: Obesity, Exercise, Metabolism, and Aggressive Prostate Cancer
Session Chairperson: June M. Chan, University of California, San Francisco, CA
8:00 a.m.-10:00 a.m.
Metabolic aspects of prostate cancer
Michael N. Pollak, Jewish General Hospital, Montreal, QC, Canada
Obesity, its sequelae, and prostate cancer risk and outcomes
Elizabeth A. Platz, Johns Hopkins University, Baltimore, MD
The role of metabolism in prostate cancer
Matthew G. Vander Heiden, MIT Koch Institute for Integrated Cancer Research, Cambridge, MA
Plenary Session 2: Can Prostate Cancer Be Prevented?
Session Chairperson: Peter H. Gann, University of Illinois, Chicago, IL
10:30 a.m.-12:30 p.m.
Forging ahead with prostate cancer prevention
Peter H. Gann
Chemopreventive agent development for prostate cancer: Is there a future?
Maarten C. Bosland, University of Illinois, Chicago, IL
Fish oil, omege-3 fatty acids, and prostate cancer
William J. Aronson, University of California – Los Angeles, Los Angeles, CA
Discussant: Meir J. Stampfer, Harvard School of Public Health, Boston, MA
Plenary Session 3: Genetic Susceptibility to Prostate Cancer: From Rare to Common Variants
Session Chairperson: Kathleen A. Cooney, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI
2:30 p.m.-4:30 p.m.
Rare penetrant prostate cancer genes (BRCA1,2 and HOXB13)
Kathleen A. Cooney
Genetic risk for prostate cancer in racially diverse populations
John S. Witte, University of California, San Francisco, CA
Current status of common prostate cancer risk-associated SNPs and their potential clinical utilities
Jianfeng Xu, Wake Forest School of Medicine, Winston-Salem, NC
Short Talks from Proffered Papers
Session Chairperson: Howard R. Soule, Prostate Cancer Foundation, Santa Monica, CA
4:45 p.m.-5:25 p.m.
Monitoring copy number aberration dynamics in sequential plasma samples from castration-resistant prostate cancer (CRPC) patients
Gerhardt Attard, The Institute of Cancer Research and the Royal Marsden, Sutton, Surrey, United Kingdom
Frequency and characterization of circulating tumor cell (CTC) populations in metastatic castration-resistant prostate cancer (mCRPC)
Ryan Dittamore, Epic Sciences, Inc., La Jolla, CA
Development and validation of a lifestyle score for prevention of lethal prostate cancer
Stacey A. Kenfield, University of California - San Francisco, San Francisco, CA
Urinary melatonin levels, sleep disruption, and risk of prostate cancer
Sarah C. Markt, Harvard School of Public Health, Boston, MA
PTEN loss together with ERG overexpression correlates with shorter survival after radical prostatectomy
Andrew Erickson, Institute for Molecular Medicine Finland, Helsinki, Finland
Coordinate induction of autophagy and apoptosis by wildtype p53 in prostate cancer cells
Chris Albanese, Georgetown University Medical Center, Washington, DC
Patient-specific kinase activation patterns in lethal metastatic castration-resistant prostate cancer
Justin M. Drake, University of California - Los Angeles, Los Angeles, CA